Gesellschaft Deutscher Chemiker
Keine Benachrichtigungen
Sie haben noch keine Lesezeichen
Abmelden

Artikel

Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity

ChemistryOpen, März 2024, DOI. Login für Volltextzugriff.

Von Wiley-VCH zur Verfügung gestellt

The objective of this study was to assess the inhibitory effect of modified cabotegravir derivatives on the activity of esophageal cancer KYSE30 cells. Results showed that compounds 5b and 5h effectively inhibited the migration and invasion of KYSE30 cells and induced apoptosis and may be involved in the stat3 and smad2/3 signal pathway. Based on these findings, we can consider these compounds as potential lead candidates for the treatment of esophageal squamous cell carcinoma.


Abstract

Structural modification based on existing drugs, which ensures the safety of marketed drugs, is an essential approach in developing new drugs. In this study, we modified the structure of cabotegravir by introducing the front alkyne on the core structure through chemical reaction, resulting in the synthesis of 9 compounds resembling 1,2,3-triazoles. The potential of these new cabotegravir derivatives as tumor suppressors in gastrointestinal tumors was investigated. Based on the MTT experiment, most compounds showed a reduction in the viability of KYSE30 and HCT116 cells. Notably, derivatives 5b and 5h exhibited the most significant inhibitory effects. To further explore the effects of derivatives 5b and 5h on gastrointestinal tumors, KYSE30 cells were chosen as a representative cell line. Both derivatives can effectively curtail the migration and invasion capabilities of KYSE30 cells and induce apoptosis in a dose-dependent manner. We further demonstrated these derivatives induce cell apoptosis in KYSE30 cells by inhibiting the expression of Stat3 protein and Smad2/3 protein. Based on the above results, we suggest they show promise in developing drugs for esophageal squamous cell carcinoma.

Zum Volltext

Überprüfung Ihres Anmeldestatus ...

Wenn Sie ein registrierter Benutzer sind, zeigen wir in Kürze den vollständigen Artikel.